Sun Pharmaceutical is planning acquisitions in Europe and is in talks with German drug maker Stada Arzneimittel AG.
The overseas acquisition is a part of strategic move to broaden its geographic breadth. Sun Pharma has followed a strategy of acquiring under-performing or unprofitable companies and merging their operations to its company.
The company is planning to raise $1 Bn for the acquisitions as the market value of the German drug maker is around $1.7 Bn. Sun Pharma has about $927 Mn cash on its balance sheet.
Deutsche Securities Mauritius Limited has sold its 1.95 percent stake in Jubilant Life Sciences Limited, a global life sciences and pharmaceutical company, for just over INR122 crore. The sale of the stake was performed as an open market transaction, and purchased by Citigroup Global Markets Mauritius Pvt. Ltd.